Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > MHLW Panel on Generic Industry Structure
MHLW Panel on Generic Industry Structure
-
Generic Firms Required to Disclose Supply Info from June after Pilot Rollout of Company Indicators
February 5, 2024
-
Health Ministry Panel Explores Vision for Generic Industry, Eyes Structural Reform in 5 Years
December 26, 2023
-
Authorized Generics Cannot be Regulated Now but Must Be Watched Closely: MHLW Panel Members
December 5, 2023
-
Generic Study Group Discusses Industry Shake-Up through Consortia
November 14, 2023
-
MHLW Panel Proposes Assessing Generic Makers’ Efforts toward Stable Supplies, Reflecting Results in Pricing
October 12, 2023
-
MHLW Proposes Curbing Entries of Generic Makers That Threaten Stable Supplies
September 20, 2023
-
MHLW Generics Study Group Discusses Yardsticks to Gauge Manufacturers’ Efforts towards Stabilizing Supplies
August 22, 2023
-
Generics Panel Initiates Debate toward Proposing Stable Supply Measures, Interim Report Slated for October
August 1, 2023
-
Panel on Generic Industry to Boot Up July 31, Report Expected by Fall
July 25, 2023
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…